Shares of Wave Life Sciences (WVE) were surging after the company highlighted its WVE-007 program at its Annual Research Day, calling the obesity treatment a potential best-in-class INHBE-siRNA that leverages proprietary chemistry for enhanced interactions with Ago2. Single doses of the treatment result in dose-dependent weigh loss and reduction of visceral fat without affecting muscle mass in mice, the company said, addidng that precliniccal datat support INHBE GalNAc-siRNA as a single agent for healthy weight loss. Wave Life added that treatment with the drug is expected to improve key measures of cardiometabolic health, and improves insulin sensitivity, cellular anergetics, and beiging of white adidpose tissue. “WVE-007 has potential to be a convenient therapeutic option to drive fat loss, while preserving muscle,” the company said, addidng that WVE-007 is currently being evaluated as a monotherapy in the ongoing INLIGHT clinical study. Wave Life shares are up over 15% in afternoon trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- iBio price target raised to $6 from $5 at Oppenheimer
- Promising Potential of Wave Life Sciences’ WVE-007 Program: A Buy Rating Based on Efficacy, Safety, and Long-term Growth Prospects
- Wave Life Sciences Advances in Duchenne Muscular Dystrophy Study with WVE-N531
- Wave Life Sciences’ New Study on WVE-N531: What Investors Need to Know
- Wave Life Sciences Advances WVE-006 Study for AATD Treatment